Enanta is committed to developing new treatments for viral infections and liver diseases. Enanta has active research and development programs in areas such as Non-Alcoholic Steatohepatitis, (NASH), Primary Biliary Cholangitis, (PBC), Respiratory Syncytial Virus, (RSV) and Hepatitis B Virus (HBV).
If you are a healthcare professional interested in learning more about Enanta’s clinical trials, please contact: Nathalie Adda, MD at nadda@enanta.com.
Learn more about any of our clinical trials described below by clicking the ClinicalTrials.gov. identifier listed below the description of the trial.
Primary Biliary Cholangitis
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Clinicaltrials.gov identifier: NCT03394924
Non-Alcoholic Steatohepatitis
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Clinicaltrials.gov identifier: NCT03421431
Respiratory Syncytial Virus
A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered EDP-938 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model.
Clinicaltrials.gov identifier: NCT03691623